These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 2472883)

  • 1. Phase I trial of N-(phosphonacetyl)-L-aspartate, methotrexate, and 5-fluorouracil with leucovorin rescue in patients with advanced cancer.
    Kemeny N; Schneider A; Martin DS; Colofiore J; Sawyer RC; Derby S; Salvia B
    Cancer Res; 1989 Aug; 49(16):4636-9. PubMed ID: 2472883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uridine allows dose escalation of 5-fluorouracil when given with N-phosphonacetyl-L-aspartate, methotrexate, and leucovorin.
    Seiter K; Kemeny N; Martin D; Schneider A; Williams L; Colofiore J; Sawyer R
    Cancer; 1993 Mar; 71(5):1875-81. PubMed ID: 8448752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved therapeutic index with sequential N-phosphonacetyl-L-aspartate plus high-dose methotrexate plus high-dose 5-fluorouracil and appropriate rescue.
    Martin DS; Stolfi RL; Sawyer RC; Spiegelman S; Young CW
    Cancer Res; 1983 Oct; 43(10):4653-61. PubMed ID: 6603903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma.
    Grem JL; McAtee N; Steinberg SM; Hamilton JM; Murphy RF; Drake J; Chisena T; Balis F; Cysyk R; Arbuck SG
    Cancer Res; 1993 Oct; 53(20):4828-36. PubMed ID: 8402669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II trial of biochemical modulation using N-phosphonacetyl-L-aspartate, high-dose methotrexate, high-dose 5-fluorouracil, and leucovorin in patients with adenocarcinoma of unknown primary site.
    Kelsen D; Martin DS; Colofiore J; Sawyer R; Coit D
    Cancer; 1992 Oct; 70(7):1988-92. PubMed ID: 1381991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-Ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma.
    Cao S; Rustum YM; Spector T
    Cancer Res; 1994 Mar; 54(6):1507-10. PubMed ID: 8137256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection.
    Erlichman C; Donehower RC; Speyer JL; Klecker R; Chabner BA
    J Natl Cancer Inst; 1982 Feb; 68(2):227-31. PubMed ID: 6950156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine riboside: optimization of 6-methylmercaptopurine riboside dose and schedule through biochemical analysis of sequential tumor biopsy specimens.
    O'Dwyer PJ; Hudes GR; Colofiore J; Walczak J; Hoffman J; LaCreta FP; Comis RL; Martin DS; Ozols RF
    J Natl Cancer Inst; 1991 Sep; 83(17):1235-40. PubMed ID: 1714507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer.
    Hageboutros A; Rogatko A; Newman EM; McAleer C; Brennan J; LaCreta FP; Hudes GR; Ozols RF; O'Dwyer PJ
    Cancer Chemother Pharmacol; 1995; 35(3):205-12. PubMed ID: 7805178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of N-phosphonacetyl-L-aspartate, recombinant interferon-alpha, and fluorouracil infusion in advanced squamous cell carcinoma of the head and neck.
    Langer CJ; Schaebler D; Sauter E; DeMaria D; Johnson C; Reilly DM; Clark J; Leighton J; Aks C; Litwin S; Ridge JA
    Head Neck; 1998 Aug; 20(5):385-91. PubMed ID: 9663665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies.
    Ardalan B; Sridhar KS; Benedetto P; Richman S; Waldman S; Morrell L; Feun L; Savaraj N; Fodor M; Livingstone A
    Cancer; 1991 Sep; 68(6):1242-6. PubMed ID: 1873776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-(phosphonacetyl)-L-aspartate and calcium leucovorin modulation of fluorouracil administered by constant rate and circadian pattern of infusion over 72 hours in metastatic gastrointestinal adenocarcinoma.
    Grem JL; Yee LK; Schuler B; Hamilton JM; Chen AP; Chabuk C; Grollman F; Grabenc M; Allegra CJ; Takimoto CH
    Ann Oncol; 2001 Nov; 12(11):1581-7. PubMed ID: 11822758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of the weekly intravenous push schedule of 5-fluoro-2'-deoxyuridine +/- N-phosphonacetyl-L-aspartate in mice bearing advanced colon carcinoma 26.
    van Laar JA; Durrani FA; Rustum YM
    Cancer Res; 1993 Apr; 53(7):1560-4. PubMed ID: 8453623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of low dose N-phosphonacetyl-L-aspartic acid and high dose 5-fluorouracil administered concomitantly with radiation therapy for unresectable localized adenocarcinoma of the pancreas.
    Ardalan B; Ucar A; Reddy R; Livingstone AS; Markoe A; Schwade J; Richman SP; Donofrio K
    Cancer; 1994 Oct; 74(7):1869-73. PubMed ID: 8082092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer.
    O'Dwyer PJ; Paul AR; Walczak J; Weiner LM; Litwin S; Comis RL
    J Clin Oncol; 1990 Sep; 8(9):1497-503. PubMed ID: 2391557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate (PALA) is inactive in advanced pancreatic carcinoma.
    Harstrick A; Köhne CH; Hiddemann W; Preusser P; Strumberg D; Berns T; Seeber S; Wilke H; Schmoll HJ
    Ann Oncol; 1997 Sep; 8(9):917-8. PubMed ID: 9358946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of high dose 5-fluorouracil and high dose Leucovorin with low dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies.
    Ardalan B; Stridhar K; Reddy R; Benedetto P; Richman S; Waldman S; Morrell L; Feun L; Savaraj N; Livingstone A
    Int J Radiat Oncol Biol Phys; 1992; 22(3):511-4. PubMed ID: 1735689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside (MMPR), and leucovorin in patients with advanced cancer.
    Hageboutros A; Hudes GR; Greene F; LaCreta FP; Brennan J; O'Dwyer PJ
    Invest New Drugs; 1997; 15(2):139-45. PubMed ID: 9220293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate in patients with advanced colorectal cancer. Results of a phase II study.
    Köhne CH; Harstrick A; Hiddemann W; Schöffski P; Wilke H; Bokemeyer C; Dörken B; Schmoll HJ
    Eur J Cancer; 1997 Oct; 33(11):1896-9. PubMed ID: 9470854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers.
    Ardalan B; Singh G; Silberman H
    J Clin Oncol; 1988 Jun; 6(6):1053-8. PubMed ID: 3373260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.